Study: Gill 2025, PLoS One
Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial
Citation
Gill B, Wessels JM, Hayes CL, Ratcliffe J et al (2025). PLoS One. PubMed id 39836666.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Probiotics and gut health Tier B moderate
A African, Caribbean and Black women aged 18 to 49 in the Greater Toronto Area (50 enrolled, 41 finished) (n=50)
Randomised, open-label phase 1 pilot of vaginal estrogen, a vaginal probiotic, or both, for 30 days (vaginal health, not gut).
The trial was feasible (80 per cent enrolment, 82 per cent retention, 93 per cent adherence) and safe. There were 88 adverse events in 29 participants, 75 per cent mild, no serious events, and no clinically significant blood changes. It was not designed to show whether vaginal health improved.
As recorded in this card: Gill B, Wessels JM, Hayes CL, Ratcliffe J et al (2025), PLoS One, [primary]
Note: The one trial in Black participants I found. It tests safety and feasibility of a vaginal product, so it says nothing about gut health or yoghurt-type probiotics.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.